Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 8/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595497 | 1.00 | DDB1 (1.00) | DDB1CRBNSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21903077 | 0.85 | DDB1 (0.74) | DDB1CRBNGPR119LMNAMAPT | |
| SCHEMBL20595415 | 0.85 | DDB1 (0.74) | DDB1CRBNGPR119LMNAMAPT | |
| SCHEMBL29744797 | 0.85 | DDB1 (0.74) | DDB1CRBNGPR119LMNAMAPT | |
| SCHEMBL25122124 | 0.84 | DDB1 (0.72) | DDB1CRBNSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29947073 | 0.83 | DDB1 (0.72) | DDB1CRBNGPR119LMNAMAPT | |
| SCHEMBL21876964 | 0.81 | DDB1 (0.67) | DDB1CRBNGPR119LMNAMAPT | |
| SCHEMBL23301226 | 0.81 | DDB1 (0.67) | DDB1CRBNGPR119LMNAMAPT | |
| Hydrochloric Acid SCHEMBL29947007 | 0.80 | DDB1 (0.67) | DDB1CRBNGPR119LMNAMAPT | |
| SCHEMBL20595430 | 0.79 | DDB1 (0.74) | DDB1CRBNSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250101037-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12180225-B2 | N/O-linked degrons and degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-118440096-A | Degradation stator and degradation determinant for N/O-ligation of protein degradation | C4医药公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11459335-B2 | N/O-linked Degrons and Degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| CN-110769822-A | N/O-linked degron and degron bodies for protein degradation | C4医药公司 | 2020-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885SMN1; SMN2 3500/4885 |
| US-20250101037-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885SMN1; SMN2 3500/4885 |
| US-12180225-B2 | N/O-linked degrons and degronimers for protein degradation | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885SMN1; SMN2 3500/4885 |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBLC, CBL | DDB1 365/4885CRBN 1/4885SMN1; SMN2 3886/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885SMN1; SMN2 3500/4885 |
| US-11459335-B2 | N/O-linked Degrons and Degronimers for protein degradation | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885SMN1; SMN2 3500/4885 |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885SMN1; SMN2 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.